FIRAZYR General Drug Use-Results Survey (Japan)

CompletedOBSERVATIONAL
Enrollment

179

Participants

Timeline

Start Date

November 20, 2018

Primary Completion Date

July 29, 2024

Study Completion Date

July 29, 2024

Conditions
Hereditary Angioedema (HAE)
Interventions
DRUG

Firazyr

Participants with Hereditary angioedema (HAE) receiving treatment with Icatibant acetate (Firazyr) as prescribed by their physician following locally approved prescribing information.

Trial Locations (18)

453-0046

Nagoya-city, Nagoya

441-8570

Toyohashi-city, Toyohashi

371-8511

Maebashi-city, Maebashi

070-0034

Asahikawa-city, Asahikawa

074-0006

Fukagawa-city, Fukagawa

077-0011

Rumoi-city, Rumoi

002-8072

Sapporo-city, Sapporo

309-1703

Kasama-city, Kasama

625-8585

Maizuru-city, Maizuru

596-0042

Kishiwada-city, Kishiwada

569-0096

Takatsuki-city, Takatsuki

350-8550

Kawagoe-city, Kawagoe

340-0041

Soka-city, Sōka

410-0302

Numazu-city, Numazu

427-8502

Shimada-city, Shimada

425-0088

Yaezu-city, Yaezu

190-0014

Tachikawa-city, Tachikawa

950-1197

Niigata-city, Niigata

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Takeda

INDUSTRY

lead

Shire

INDUSTRY